QNCX FY2029 EPS Boosted by Brookline Capital Management

Key Points

• Brookline Capital Management has increased its FY2029 earnings per share estimate for Quince Therapeutics from $0.48 to $0.54, while the consensus estimate for the company's current full-year earnings is ($1.21) per share.
• Quince Therapeutics reported a quarterly EPS of (\$0.34), missing the consensus estimate of (\$0.28) by (\$0.06) during its last earnings announcement on August 11th.
• Institutional investors have been active, with several hedge funds, including Geode Capital Management and Northern Trust, boosting their stakes in Quince Therapeutics, indicating increased confidence in the company's future performance.

Quince Therapeutics, Inc. (NASDAQ:QNCX - Free Report) - Investment analysts at Brookline Capital Management boosted their FY2029 EPS estimates for shares of Quince Therapeutics in a research report issued to clients and investors on Tuesday, August 12th. Brookline Capital Management analyst K. Raja now anticipates that the company will post earnings of $0.54 per share for the year, up from their prior forecast of $0.48. The consensus estimate for Quince Therapeutics' current full-year earnings is ($1.21) per share.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.06).

QNCX has been the topic of several other research reports. Wall Street Zen downgraded shares of Quince Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. JMP Securities dropped their target price on shares of Quince Therapeutics from $9.00 to $8.00 and set a "market outperform" rating on the stock in a research report on Tuesday, August 12th. Citigroup began coverage on shares of Quince Therapeutics in a research report on Tuesday, August 5th. They set an "outperform" rating on the stock. D. Boral Capital reissued a "buy" rating and set a $4.00 target price on shares of Quince Therapeutics in a research report on Friday. Finally, Citizens Jmp began coverage on shares of Quince Therapeutics in a research report on Tuesday, August 5th. They set a "strong-buy" rating and a $9.00 target price on the stock. Three analysts have rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $8.14.

Quince Therapeutics Stock Down 2.4%

Shares of Quince Therapeutics stock traded down $0.04 on Thursday, reaching $1.63. The stock had a trading volume of 92,969 shares, compared to its average volume of 236,932. The company has a 50 day moving average price of $1.62 and a 200 day moving average price of $1.36. The company has a quick ratio of 5.00, a current ratio of 5.00 and a debt-to-equity ratio of 1.45. Quince Therapeutics has a 1 year low of $0.5609 and a 1 year high of $2.45. The stock has a market capitalization of $87.55 million, a P/E ratio of -1.50 and a beta of 1.02.

Institutional Trading of Quince Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC lifted its stake in Quince Therapeutics by 48.4% during the 1st quarter. Virtu Financial LLC now owns 43,332 shares of the company's stock valued at $58,000 after acquiring an additional 14,128 shares during the period. Northern Trust Corp lifted its stake in shares of Quince Therapeutics by 48.5% in the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company's stock valued at $94,000 after purchasing an additional 16,501 shares during the period. Bridgeway Capital Management LLC lifted its stake in shares of Quince Therapeutics by 20.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company's stock valued at $212,000 after purchasing an additional 22,200 shares during the period. XTX Topco Ltd acquired a new position in shares of Quince Therapeutics in the 2nd quarter valued at $37,000. Finally, Two Sigma Investments LP acquired a new position in shares of Quince Therapeutics in the 4th quarter valued at $57,000. 30.75% of the stock is currently owned by institutional investors and hedge funds.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.